August 20, 2026

News, minutes after it breaks

Latest

Home  / Business

Moderna stock soars 177%, Merck jumps 12% after cancer vaccine shows promise in late-stage trial

Image: CNBC

The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.

CNBC reported this story. Read the full report on cnbc.com →

This is a short summary. CNBC wrote and published the full report.

Continue on cnbc.com →

More in Business

Leave a Reply

Your email address will not be published. Required fields are marked *